TABLE 3.

Cox Proportional Hazards Model According to Class Risk in Terms of disease‐free and Overall Survival

Characteristic	Patients at risk	Disease‐free survival			Overall survival
		No. of events	HR (95% CI)	p	No. of events	HR (95% CI)	p
2020 ESGO/ESTRO/ESP risk group with unknown molecular classification	137	40	1.02 (0.74–1.42)	.884	40	1.40 (0.98–2.00)	.063
Low	38	9	1 (reference)		5	1 (reference)
Intermediate	46	16	1.49 (0.66–3.38)	.341	9	1.31 (0.43–3.94)	.636
High‐intermediate	39	12	1.29 (0.54–3.07)	.567	15	2.58 (0.93–7.19)	.069
High	14	3	0.97 (0.26–3.60)	.964	5	2.1 (0.59–7.51)	.255
2020 ESGO/ESTRO/ESP risk group with known molecular classification	127	34	1.25 (0.92–1.71)	.157	30	1.79 (1.24–2.59)	.002
Low	35	6	1 (reference)		3	1 (reference)
Intermediate	36	12	2.10 (0.79–5.61)	.139	5	1.43 (0.34–6.03)	.626
High‐intermediate	31	6	1.14 (0.37–3.55)	.821	10	3.19 (0.87–11.7)	.081
High	25	10	2.69 (0.97–7.43)	.057	12	5.16 (1.44–18.48)	.012
Molecular prognostic profile	127	34	1.50 (0.98–2.30)	.062	34	2.03 (1.24–3.34)	.005
Favorable	46	7	1 (reference)		6	1 (reference)
Intermediate	49	16	2.43 (0.99–5.90)	.051	9	1.24 (0.44–3.51)	.689
Unfavorable	32	11	2.43 (0.94–6.29)	.067	15	3.55 (1.37–9.19)	.009

Abbreviations: CI, confidence interval; ESGO, European Society of Gynaecological Oncology; ESP, European Society of Pathology; ESTRO, European Society for Radiotherapy and Oncology; HR, hazard ratio.

See also pages 000–000.